15265 - ISTH "Tissue Factor and Cancer"
Dr. Ruf’s presentation will cover mechanisms supported by the tissue factor (TF) pathway in primary tumor growth and metastasis. Interventional strategies to block TF’s procoagulant and signaling activities in malignancy will be discussed.
Tissue factor-positive microparticles in cancer-associated thrombosis – Nigel Mackman
Dr. Mackman’s presentation will describe the measurement of tissue factor (TF)-positive microparticles (MPs) in plasma samples from cancer patients. It will also summarize studies that show a relationship between elevated levels of MP-TF activity and VTE in pancreatic cancer patients but not other types of cancer patients. Other mechanisms of cancer-associated thrombosis will be discussed.
Accreditation Statement
Target Audience
Physician scientists and translational research in thrombosis and hemostasis research and oncology
Learning Objectives
At the conclusion of this activity, I will be able to:
- Understand the contributions of TF initiated coagulation and cell signaling to tumor progression
- Obtain an overview of preclinical efficacy of inhibitors targeting TF in animal models of metastasis and tumor growth
- Acquire insights into open questions and directions of translational research in the field of cancer and thrombosis
- Provide information on the strengths and weaknesses of the different methods to measure levels of TF+ MPs in plasma samples from patients.
- The potential utility of MP-TF activity as a biomarker of thrombotic risk in patients will be discussed.
Name | Company | Role |
Chris Ward, MD | Bayer | Advisory Board, Speaker |
| Pfizer, BMS | Advisory Board, Speaker |
| Boehringer-Ingelheim | Advisory Board, Speaker |
| Alexion | Advisory Board |
| Medimark | Steering Committee Member, Speaker |
Geoff Barnes | BMS, Pfizer, Blue Cross Blue Shield of Michigan | Primary Investigator & Co-Investigator |
Yukio Ozaki | Sysmex | Advisory Board |
Wolfram Ruf | Iconic Therapeutics | Consultant |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Price
Required Hardware/software
To view the webcast on your computer go to https://www.isth.org/ click the Events/Webinars tab and view the ISTH 2015 Archived Webinars